Kinesin Like Protein KIF11 Pipeline Landscape and Therapeutic Assessment in H2 2017


Published on : Nov 13, 2017

Albany, New York, November 13, 2017: The latest pipeline review has been done by research experts which encapsulate vital information on the Kinesin Like Protein KIF11 targeted therapeutics with well-updated data in H1 2017. This analysis has been added to the market intelligence repository of Market Research Hub (MRH), with the title of “Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin-Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) - Pipeline Review, H1 2017”. The guide also covers the descriptive pharmacological action of the therapeutics on the basis of complete research & development history, latest news and press releases from company/ university sites.

Kinesin spindle protein (KSP) is a member of the kinesin superfamily of microtubule-based motors. It plays an important role in mitosis. Removal of Kinesin-like protein KIF11 prevents centrosome migration and causes cell arrest in mitosis.

Initially, the report provides a snapshot of the global therapeutic landscape of Kinesin Like Protein with its overview, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. This report on Kinesin Like Protein KIF11 market is beneficial for readers and has been compiled by conducting both primary and secondary research and analyzes the market on the basis of its pipeline review. New entrants in this market can plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics.

Furthermore, this pipeline study covers products from therapy areas including Oncology and Immunology which include indications Ovarian Cancer, Acute Myelocytic Leukemia, Bladder Cancer, Breast Cancer, Colorectal Cancer, Head And Neck Cancer, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Kidney Cancer (Renal Cell Cancer), Liver Cancer, Lung Cancer, Lymphoma, Melanoma, Multiple Myeloma (Kahler Disease) and Non-Small Cell Lung Cancer. Apart from that, the study features detailed drug profiles for the pipeline products which includes product description, R&D brief, licensing and collaboration details, descriptive MoA and other developmental activities. The drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information.

Moreover, the pipeline guide also reviews key companies involved in therapeutics developments of Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) and enlists all their major and minor projects. Leading companies mentioned in the report are 4SC AG, Merck & Co Inc, Kyowa Hakko Kirin Co Ltd and Novartis AG.

Request a Sample with TOC in a PDF format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=1361344

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top